

NEWS RELEASE

Anti-Tau Antibody created by Teijin Pharma and developed by Merck & Co., Inc., Kenilworth NJ USA Enters Clinical Development

Tokyo, Japan, February 1, 2022 --- [Teijin Pharma Limited](#), the core company of the [Teijin Group](#)'s healthcare business, announced today that [Merck & Co., Inc., Kenilworth, NJ, USA](#), a leading global biopharmaceutical company (known as MSD outside the U.S. and Canada), has initiated a clinical trial of an antibody candidate targeting tau being developed under license from Teijin Pharma. Teijin Pharma has received a milestone payment from Merck & Co., Inc., Kenilworth, NJ USA.

The anti-tau antibody, which Teijin Pharma created is designed specifically to bind to abnormally hyperphosphorylated tau proteins.

The number of dementia patients worldwide is predicted to rise to nearly 76 million in 2030 and then to 139 million in 2050, according to research performed by [Alzheimer's Disease International](#). Two pathological changes in the brain are considered to be the cause of Alzheimer's disease: the extracellular deposition of amyloid β peptide and neurofibrillary tangles resulting from intracellular accumulation of hyperphosphorylated tau proteins.

Teijin Pharma and Merck & Co., Inc., Kenilworth, NJ USA signed a license agreement in May 2017 under which Merck & Co., Inc., Kenilworth, NJ USA has exclusive worldwide rights to develop, manufacture and commercialize Teijin Pharma's anti-tau antibody. In exchange, Teijin Pharma received an upfront payment and is eligible to receive development, regulatory and sales milestone payments as well as royalties on any product sales. Teijin Pharma also retains an option to co-promote an approved product in Japan.

The agreement with Merck & Co., Inc., Kenilworth, NJ USA is one of many alliances that Teijin Pharma has entered for products that the company has developed in-house with the aim of realizing innovative and effective treatments to enhance the quality of life of patients. Merck & Co., Inc., Kenilworth, NJ USA's strong neuroscience expertise makes it well suited to maximize the potential of this antibody candidate.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon

fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement “Human Chemistry, Human Solutions,” Teijin aims to be a company that supports the society of the future. The group comprises more than 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 836.5 billion (USD 7.7 billion) and total assets of JPY 1,036.4 billion (USD 9.5 billion) in the fiscal year that ended on March 31, 2021.

Press Contact

Corporate Communications

Teijin Limited

pr@teijin.co.jp